Biotech Values

[DewDiligence]

PFE-AGN pushing hard for a deal, according to sources:

http://www.bloomberg.com/news/articles/2015-10-30/pfizer-allergan-said-to-aim-to-agree-on-deal-by-thanksgiving

Pfizer Inc. and Allergan Plc are making progress on the year’s biggest acquisition and are working toward agreeing on a deal as early as next month, people with knowledge of the matter said.

The drugmakers are keen on a friendly deal and hope to agree on the terms of the takeover, including who will lead the combined company, by Thanksgiving, the people said, asking not to be identified as the discussions are private.

While Pfizer is lining up banks to finance a deal, any offer would contain enough shares to allow the company to shift its base to Allergan’s lower-taxed Irish domicile [i.e. the deal will include enough PFE shares to give AGN at least a 40% equity stake in the merged company, which is the US Treasury’s new threshold for a tax inversion].

Allergan is expecting to get more than $350 a share from Pfizer, though talks have not yet gotten into specifics, one person close to the target company said.